← Leaderboards
Paul H Gordon
Columbia University Health Sciences
$4,461,311
Attributed
$4,461,311
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–07$2M$1.5M$1M$500K$0
'05
'06
'07
Funding mix
By agency
NIH$4,461,311 · 2
By mechanism
R01$4,456,795 · 1
M01$4,516 · 1
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Scott A Small$25,024,830
- Michio Hirano$20,704,569
- Joyce K Anastasi$14,237,944
- Habibul Ahsan$55,484,435
- Yaakov Stern$60,326,200
Others in their field
Top investigators on “Motor Neurons”
- Merit E Cudkowicz · Massachusetts General Hospital$50,666,157
- Jerrold L Vitek · University Of Minnesota$28,920,065
- Daniel M Corcos · Northwestern University$27,398,302
- Richard A Andersen · California Institute Of Technology$25,841,240
- Martyn D Goulding · Salk Institute For Biological Studies$22,530,165
- Peter L Strick · University Of Minnesota Twin Cities$20,725,006
Research focus
Motor NeuronsAmyotrophic Lateral SclerosisData Collection Methodology /EvaluationPathologic ProcessStatistics /BiometryClinical Trial Phase IiiDrug Screening /EvaluationCaliforniaBrainAnimal ModelCellsCessation Of LifeClinical ResearchCell DeathCaspase-3ApoptoticCompanionsCommunication, PersonalData AnalysesCaspase-1Data ManagementDeteriorationDisease ProgressionClinical Trials, Phase Iii
Grant awards (7)
Phase III Trial of Minocycline in ALS:I-Clinical Center$56,100
R01 · FY2007 · NS · contact PI
Phase III Trial of Minocycline in ALS:I-Clinical Center$22,800
R01 · FY2007 · NS · contact PI
Phase III Trial of Minocycline in ALS:I-Clinical Center$891,840
R01 · FY2006 · NS · contact PI
Phase III Trial of Minocycline in ALS:I-Clinical Center$1,050,254
R01 · FY2005 · NS
PHASE II TRIAL OF GLATIRAMER ACETATE INAMYOTROPHIC LATERAL SCLEROSIS$4,516
M01 · FY2005 · RR
Phase III Trial of Minocycline in ALS:I-Clinical Center$1,136,760
R01 · FY2004 · NS
Phase III Trial of Minocycline in ALS:I-Clinical Center$1,299,041
R01 · FY2003 · NS